Dong-E-E-Jiao Stock: Valuation and P/E
000423.SZDong-E-E-Jiao trades at a P/E of 18.9 (Drug Manufacturers (Specialty & Generic) median 30.3, own median of recent years 22.6). It was last lower at the fiscal 2025 year end (18.1).
Daily figure as of 20 Nov 2026
Against Its Own Valuation History
Each fiscal year is shown with its P/E on the year-end date, using the price at the time. From 2016 to 2025 the P/E at fiscal year end ranged from 12.4 (2018) to 576.9 (2020). Fiscal 2019 ended in a loss, so it has no P/E. From 2020 to 2025 it fell five years in a row.
P/E at Each Fiscal Year End
Figures as a table
| Year | P/E |
|---|---|
| 2016 | 19 |
| 2017 | 19.3 |
| 2018 | 12.4 |
| 2020 | 576.9 |
| 2021 | 71.7 |
| 2022 | 33.6 |
| 2023 | 27.6 |
| 2024 | 25.9 |
| 2025 | 18.1 |
P/E of Industry Peers
Dong-E-E-Jiao's P/E is lower than that of 19 of 26 other profitable stocks in the Drug Manufacturers (Specialty & Generic) industry.
| Stock | P/E | Own median |
|---|---|---|
| China Resources Sanjiu Medical & Pharmaceutical | 13.6 | 16.9 |
| Supernus | 7.7 | 16.9 |
| Gland Pharma | 44.0 | 37.7 |
| Sumitomo Pharma | 18.3 | 13.4 |
| Dong-E-E-Jiao | 18.9 | 22.6 |
| Ipca Laboratories | 33.7 | 35.3 |
| Rovi | 16.4 | 25.2 |
| Siegfried Holding | 17.3 | 3.4 |
| Bausch Health Companies | no data | 9.3 |
The eight peers closest in market value, largest first. Trailing twelve-month P/E as of 20 Nov 2026, loss makers have none.
Earnings Yield and Interest Rates
Put the other way round, earnings per share over the last twelve months equal 5.3% of the share price. That is the earnings yield. Ten-year government bonds of the home country (China) yielded 2.3% on average over the last five years, the same rate the fair value uses. So the earnings yield is 3.0 percentage points higher. Unlike interest, earnings are not guaranteed. They fluctuate and can disappear.
Data and Required Disclosures
- ; time horizon around 12 months
- Rated Strong since 7 Nov 2026; valuation signal Fairly valued since 18 Nov 2026
- Price: closing price of 20 Nov 2026
- Amounts in US dollars at the ECB reference rate of 19 Nov 2026 ($1 = CN¥6.6667)
- Data from Financial Modeling Prep (FMP) based on the company's reports, latest fiscal year 2025. MEQIRI calculates the score and fair value itself every night.
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.
